Read news on dll3 with our app.
Read more in the app
First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer - EurekAlert!
Precision medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 expression - EurekAlert
